SL
CORT icon

Salomon & Ludwin’s Corcept Therapeutics CORT Stock Holding History

Salomon & Ludwin’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.2K Sell
895
-168
-16% -$10.1K 0.01% 339
2026
Q1 		$45.2K Buy
1,063
+402
+61% +$15K ﹤0.01% 534
2025
Q4 		$23.1K Buy
661
+28
+4% +$2.2K ﹤0.01% 788
2025
Q3 		$55.8K Buy
+633
New +$45.8K 0.01% 355

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salomon & Ludwin's CORT Position: Q2 2026 in Review

Salomon & Ludwin reduced its Corcept Therapeutics (CORT) stake by 16% in Q2 2026, selling an estimated $10.1K and leaving 895 shares worth $79.2K. The position accounts for 0.01% of the portfolio, ranked #339.

Salomon & Ludwin first reported a position in CORT in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Salomon & Ludwin held 895 shares of Corcept Therapeutics worth $79.2K as of Q2 2026.
  • Salomon & Ludwin sold 168 Corcept Therapeutics shares in Q2 2026, an estimated $10.1K.
  • Corcept Therapeutics made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #339 holding.
  • Salomon & Ludwin first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.